HC Wainwright Forecasts Lower Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Equities researchers at HC Wainwright lowered their Q3 2025 EPS estimates for shares of Sensus Healthcare in a report issued on Tuesday, August 12th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.12) per share for the quarter, down from their prior estimate of ($0.02). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.43) EPS, Q1 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.01 EPS.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%.

SRTS has been the topic of a number of other research reports. Maxim Group cut their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Lake Street Capital cut their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen lowered shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Sunday, June 22nd.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $3.44 on Thursday. The firm has a market capitalization of $56.55 million, a P/E ratio of -57.33 and a beta of 1.34. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.33. The company’s fifty day moving average price is $4.72 and its 200-day moving average price is $4.91.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new position in shares of Sensus Healthcare in the fourth quarter worth about $27,000. Barclays PLC purchased a new position in shares of Sensus Healthcare in the fourth quarter worth about $35,000. Larson Financial Group LLC purchased a new position in shares of Sensus Healthcare in the first quarter worth about $26,000. BNP Paribas Financial Markets purchased a new position in shares of Sensus Healthcare in the fourth quarter worth about $47,000. Finally, Vise Technologies Inc. acquired a new stake in Sensus Healthcare during the second quarter worth about $52,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.